Investors & Media

News

November 13, 2023

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

November 7, 2023

NGM Bio to Participate in Upcoming Investor Conferences

November 2, 2023

NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights

October 11, 2023

NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®

August 3, 2023

NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights

May 25, 2023

NGM Bio to Participate in Upcoming Investor Conferences

May 8, 2023

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023

May 4, 2023

NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

March 1, 2023

NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference

February 28, 2023

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

Displaying 1 - 10 of 12

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com